News and reporting on cell-free DNA testing.
The firm won't have to pay off its unsecured convertible notes until 2026 to investors, including Patrick Soon-Shiong's Nant Capital.
The researchers found that the reliable sampling of rare circulating tumor DNA fragments served as the key challenge for developing liquid biopsy assays.
The Rehovot, Israel-based firm expects to soon receive marketing clearance from the US Food and Drug Administration for its methylation-based Bladder EpiCheck test.
The Israeli-based startup will use the funds to continue development of its EpiCheck methylation platform and to develop the Lung EpiCheck assay.
The firm, a University of Edinburgh spinout, will use the funding to in-license its BioCollector liquid biopsy platform and launch initial trials.
